<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196452</url>
  </required_header>
  <id_info>
    <org_study_id>CA184-557</org_study_id>
    <nct_id>NCT04196452</nct_id>
  </id_info>
  <brief_title>A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)</brief_title>
  <official_title>Long-term Follow-up of Ipilimumab-treated Pediatric Patients Enrolled in the Dutch Melanoma Treatment Registry (DMTR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, national, retrospective study consisting of pediatric patients with
      advanced (spread or unremoveable) melanoma identified in the DMTR in the Netherlands
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 18, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2029</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Adverse Events (AEs) Grades 3-4</measure>
    <time_frame>up to 10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline assessment of population demographics</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline assessment of comorbidities</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline assessment of disease characteristics</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline assessment of treatment history</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of ipilimumab dose exposure</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in ipilumamb treatment: dose interruptions/discontinuations</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Ipilimumab dose frequency</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of ipilimumab treatment duration</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of ipilimumab number of infusions</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of physical growth and development</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm A: participants 12 to under 18</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: participants under 12</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Arm A: participants 12 to under 18</arm_group_label>
    <arm_group_label>Arm B: participants under 12</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes participants who are under 18 years old who are diagnosed
        with advanced (unresectable or metastatic) melanoma who have been treated with ipilimumab
        and enrolled in the DMTR
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trials, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Less than 18 years of age at first dose of monotherapy Ipilimumab used for treatment
             of advanced melanoma

          -  Histological or cytological confirmation of advanced (unresectable or metastatic)
             melanoma

        Exclusion Criteria:

        -Participation in a clinical trial within the past 4 weeks prior to first dose with
        ipilimumab or concurrently

        Other inclusion/exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

